MorphoSys Nominates First Pre-Development Program in Antibody Collaboration
News Sep 25, 2008
In a first, pre-development step, Novartis will fund the companies' joint efforts until the program reaches formal pre-clinical development. MorphoSys will recognize its share of the funding as additional revenues.
In December 2007, MorphoSys and Novartis forged one of the most comprehensive strategic alliances in the discovery and development of biopharmaceuticals. Financial terms include committed payments in excess of USD600 million over the 10-year lifetime of the agreement. Under the co-development options, MorphoSys may elect to participate in a selection of projects through cost and profit sharing with financial participation reflecting its level of investment in the respective programs. The pre-development agreement provides MorphoSys with the option to enter a formal co-development for the respective program with Novartis. Certain early stage costs in these programs are being funded by Novartis.
"Today's news marks another significant step in our plans to expand our proprietary drug development activities. This is a great opportunity for MorphoSys to become involved in developing an antibody against a very promising target together with Novartis," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys. "We see these pre-development options as an extremely valuable component of our deal with Novartis as they give us the opportunity to build our drug development capability in conjunction with one of the strongest and most experienced companies in the pharmaceutical industry."
A team of researchers has discovered a combination of pharmaceutical drugs that not only increases healthy lifespan in the microscopic worm Caenorhabditis elegans (C. elegans), but also delays the rate of ageing in them, a finding that could someday mean longer, healthier lives for humans.READ MORE
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019